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Policy Forum
T
he Global HIV Vaccine 
Enterprise convened a two-day 
workshop in May of 2007 to 
discuss humoral immune responses to 
HIV and approaches to design vaccines 
that induce viral neutralizing and 
other potentially protective antibody 
responses. The goals of this workshop 
were to identify key scientiﬁc issues, 
gaps, and opportunities that have 
emerged since the Enterprise Strategic 
Plan was ﬁrst published in 2005 [1], 
and to make recommendations that 
Enterprise stakeholders can use to plan 
new activities. 
Most effective viral vaccines work, at 
least in part, by generating antibodies 
that inactivate or neutralize the 
invading virus, and the existing data 
strongly suggest that an optimally 
effective HIV-1 vaccine should elicit 
potent antiviral neutralizing antibodies. 
However, unlike acute viral pathogens, 
HIV-1 chronically replicates in the 
host and evades the antibody response. 
This immune evasion, along with the 
large genetic variation among HIV-1 
strains worldwide, has posed major 
obstacles to vaccine development. 
Current HIV vaccine candidates do not 
elicit neutralizing antibodies against 
most circulating virus strains, and thus 
the induction of a protective antibody 
response remains a major priority for 
HIV-1 vaccine development. For an 
antibody-based HIV-1 vaccine, progress 
in vaccine design is generally gauged 
by in vitro assays that measure the 
ability of vaccine-induced antibodies 
to neutralize a broad spectrum of 
viral isolates representing the major 
genetic subtypes (clades) of HIV-
1 [2]. Although it is not known 
what magnitude and breadth of 
neutralization will predict protection 
in vaccine recipients, it is clear that 
current vaccine immunogens elicit 
antibodies that neutralize only a 
minority of circulating isolates. Thus, 
much progress needs to be made in this 
area. Also, though virus neutralization 
is considered a critical benchmark 
for a vaccine, this may not be the only 
benchmark for predicting success 
with antibody-based HIV-1 vaccine 
immunogens.
The main targets for neutralizing 
antibodies to HIV-1 are the surface 
gp120 and trans-membrane gp41 
envelope glycoproteins (Env) that 
mediate receptor and coreceptor 
binding and the subsequent membrane 
fusion events that allow the virus to 
gain entry into cells [3]. Antibodies 
neutralize the virus by binding these 
viral spikes and blocking virus entry 
into susceptible cells, such as CD4+
T cells [4,5]. In order to chronically 
replicate in the host, the virus 
exploits several mechanisms to shield 
itself against antibody recognition, 
including a dense outer coating of 
sugar molecules (N-linked glycans) 
and the strategic positioning of 
cysteine–cysteine loop structures on the 
gp120 molecule [6–8]. These shielding 
mechanisms, although highly effective, 
have vulnerabilities imposed by ﬁtness 
constraints. Information on the precise 
location and molecular structure of 
these vulnerable regions could be 
valuable for the rational design of 
improved vaccine immunogens.
Participants in the workshop 
identiﬁed four areas that, if given 
proper attention, could provide key 
information that would bring the ﬁeld 
closer to an effective antibody-based 
HIV-1 vaccine: (1) structure-assisted 
immunogen design, (2) role of Fc 
receptors and complement, (3) assay 
standardization and validation, and (4) 
immunoregulation of B cell responses.
Structure-Assisted Immunogen 
Design
Clinical studies have demonstrated that 
immunization with the gp120 surface 
unit of the HIV-1 envelope protein 
does not lead to the induction of 
potent or broadly reactive neutralizing 
antibodies. In order to develop better 
immunogens, it is likely that we will 
need a more detailed understanding of 
the atomic level structure of epitopes 
on the native envelope glycoprotein. 
Data on the X-ray crystal structure of 
liganded and unliganded partial gp120 
molecules have provided valuable 
information about the atomic level 
interaction of gp120 and neutralizing 
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antibodies [9–12]. The recent atomic 
level resolution of monoclonal 
antibody (MAb) b12 bound to the 
CD4 receptor binding site of the gp120 
molecule provides new insights into 
how successful neutralizing antibodies 
access functionally conserved regions 
of the Env glycoprotein [13]. Crystal 
structures of complete monomeric 
gp120 and gp120–gp41 trimer 
complexes in their native unliganded 
form need to be elucidated, as these 
are the natural targets for neutralizing 
antibodies. This information is needed 
for multiple genetic subtypes of the 
virus and for transmitted strains of 
the virus. Coupled with this effort 
should be a program to make necessary 
improvements in electron tomography 
technology to gain a higher resolution 
of native Env spikes as they exist on 
virus particles [14–16]. An improved 
understanding of the structural basis 
of antibody binding to the HIV-1 
Env glycoprotein will likely form the 
foundation for a rational program 
of novel vaccine design. Ongoing 
efforts to stabilize gp120 into more 
immunogenic forms or to scaffold 
conserved neutralization epitopes into 
foreign proteins may lead to more 
promising antibody responses. 
Induction of an effective neutralizing 
antibody response will require that 
a vaccine deliver to the naïve B cell 
repertoire epitopes that are both 
immunogenic (i.e., possess favorable 
properties for B cell inductive 
pathways) and antigenic (i.e., available 
for high afﬁnity antibody binding on 
functional Env spikes). Viral epitopes 
that are conserved among most viral 
strains are more likely to generate 
cross-reactive antibodies. In this regard, 
researchers have focused on a small 
number of human MAbs, from clade B 
HIV-1-infected individuals, that possess 
broadly cross-reactive neutralizing 
activity [17,18]. The cognate viral 
epitopes for these MAbs have been well 
characterized and are being evaluated 
as vaccine immunogens. However, 
for reasons that are not completely 
understood, these conserved viral 
epitopes have either been poorly 
immunogenic or have elicited 
antibodies of restricted reactivity. 
Improvements are being sought 
by introducing speciﬁc structural 
alterations [19,20] and by targeting 
autoreactive B cell pathways [21]. 
These and other efforts to improve 
the immunogenicity of conserved 
neutralization epitopes should remain 
a high priority. Workshop participants 
recognized the need to expand efforts 
to identify and characterize new 
MAbs, with special attention to MAbs 
from non-clade B HIV-1 infections. 
New technologies are now available 
that might afford an advantage for 
identifying novel antibody speciﬁcities 
that were previously undetected 
[22,23]. In addition to this focus 
on MAbs, sera from selected HIV-1-
infected individuals that can broadly 
neutralize HIV-1 isolates should be 
studied in detail. New assays allow more 
precise mapping of the polyclonal 
antibody response in these sera to 
better understand the epitopes targeted 
[5,24–26]. Such studies may reveal 
novel antibody speciﬁcities and their 
associated viral epitopes that could be 
useful for immunogen design. 
While there has been considerable 
interest in conserved epitopes, less 
attention has been paid to more 
variable epitopes that might be 
useful if administered in the form of 
a polyvalent vaccine. Of particular 
interest are the epitopes that drive 
the autologous neutralizing antibody 
response in infected individuals. These 
epitopes may be quite variable, but 
recent evidence suggests that there are 
constraints on the extent of variation 
the virus can tolerate in these regions 
[27,28]. Detailed molecular and 
immunologic studies of the autologous 
neutralization response would 
enhance our understanding of viral 
determinants that are vulnerable to 
antibody attack. Similarly, it is possible 
that combinations of antibodies will 
have desirable additive or synergistic 
effects on virus neutralization 
[29–32]. An example is seen in how 
soluble CD4 binding rearranges the 
structure of gp120 to expose the 
highly conserved coreceptor binding 
domain, which allows antibody binding 
and virus neutralization to occur 
[33,34]. Such effects of antibodies 
might be discovered by applying high 
throughput screening methods to the 
plethora of existing MAbs as well as 
new MAbs that become available in the 
future.
Role of Fc Receptors and 
Complement
Recent ﬁndings have generated 
renewed interest in so-called “non-
neutralizing” antibodies that are unable 
to directly inhibit free virus entry into 
target cells, but nonetheless exhibit 
antiviral activity mediated by the Fc 
region of the antibody molecule. 
These antibody effector mechanisms 
include complement binding and viral 
lysis, phagocytosis of antibody-coated 
virions, and antibody-dependent 
cellular cytotoxicity [35–38]. Recent 
studies have suggested examples of 
Fc-dependent antiviral effects of HIV-
1-positive serum in cases where there 
was little or no detectable activity in 
conventional neutralization assays 
[39,40].
In addition, passive transfer studies 
in a relevant monkey model suggest 
that Fc receptor (FcR) binding 
capacity of a protective antibody 
makes a substantial contribution to 
the antibody-mediated protection 
[41]. Antibody effector functions that 
mediate complement activation and 
FcR engagement on macrophages, 
dendritic cells, natural killer cells, and 
other cell types need to be evaluated 
to determine their relevance to 
HIV-1 vaccines. Assays that measure 
these antiviral antibodies should 
be standardized and used to assess 
biologic relevance in passive protection 
experiments in animal models using 
antibodies that exhibit the different 
effector functions in vitro.
Assay Standardization and 
Validation
In order to adequately monitor 
neutralization breadth and potency 
and to compare and prioritize 
immunogens, assays are needed 
that are sensitive, quantitative, high 
throughput, and have correlative 
value. Substantial improvements have 
been made in the past several years 
in assay technology and in available 
reference reagents. Thus, cumbersome 
and expensive assays using peripheral 
blood mononuclear cells (PBMC) and 
uncloned viruses are being replaced 
with assays that utilize molecularly 
cloned Env-pseudotyped viruses and 
genetically engineered target cells lines 
[2,42–45]. This new technology affords 
greater sensitivity, reproducibility, high 
throughput, and cost-effectiveness 
compared to PBMC assays, and as a 
result, it has been responsible for an 
explosion of new data. Steps are being 
taken by the Collaboration for AIDS 
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technology to multiple laboratories 
around the world and to implement a 
validated proﬁciency testing program 
to assure inter-laboratory equivalency 
in assay performance. 
Recently, several cases were 
identiﬁed where neutralization 
was considerably more potent or 
only detected in the older PBMC 
assay compared to the newer assay 
technology [43,46,47]. This raises 
important questions about current 
plans to employ a single assay for 
routine use, and it points to the need 
for a better understanding of the 
mechanisms of neutralization. Thus, 
it may be necessary to use more than 
one assay to assure that all neutralizing 
antibodies are detected. There is a 
need to standardize and compare 
neutralizing antibody assays and to 
decide which assay or combination of 
assays should be used for standardized 
assessments of vaccine-elicited 
neutralizing antibody responses. A 
major priority is to strengthen the 
standardization of the PBMC assay, 
given that it is the only assay that has 
been at least partially validated in 
passive antibody experiments in animal 
challenge models. 
Important decisions need to be 
made about the types of antibodies and 
assays that have greatest relevance to 
HIV-1 vaccines. Validation experiments 
in animals models are needed to 
determine the potential correlative 
value of new assay technologies 
that rely on the use of genetically 
engineered cells lines and Env-
pseudotyped viruses. Ideally, this would 
be done by employing several different 
assays to study the antibody response 
in a clinical efﬁcacy trial in which the 
vaccine was at least partially protective. 
Because no such vaccine is currently 
available for HIV-1, studies in animal 
models are the next best choice. In this 
regard, two animal models are widely 
used for HIV vaccine development: 
simian immunodeﬁciency virus 
(SIV) and chimeric simian-human 
immunodeﬁciency virus (SHIV) 
infection in monkeys [48]. Quantitative 
passive transfer experiments in either 
model with antibodies that exhibit 
different effector functions could be 
used to address the biological relevance 
of in vitro assays. Unfortunately, very 
few SHIVs are currently available and, 
among these, most are derived from a 
single genetic subtype (clade B) and 
exhibit properties that may not be well 
suited to assay validation [49]. The 
creation of new and better SHIVs from 
non-clade B viruses would facilitate 
assay standardization as well as vaccine 
challenge models.
Immunoregulation of B Cell 
Responses
This workshop identiﬁed several critical 
gaps in the current understanding 
of B cell regulatory pathways that 
impede a more rational development 
of an effective antibody-based HIV-
1 vaccine. For example, broadly 
neutralizing antibodies in patient 
serum bind epitopes that are present 
on monomeric gp120 [25], yet this is 
a poor immunogen for neutralizing 
antibody induction in vaccine 
recipients. Moreover, as mentioned 
above, viral epitopes for the known 
broadly neutralizing MAbs appear to 
be poorly immunogenic in infected 
individuals and as vaccine candidates. 
Insights into the immunoregulation 
of some of these latter epitopes (e.g., 
epitopes deﬁned by MAbs 2F5 and 
4E10) was provided by recent studies 
in which the MAbs were discovered to 
bind one or more self antigens [50,51], 
raising the possibility that these 
antibody speciﬁcities are subjected 
to negative regulation mechanisms, 
such as receptor editing or deletion. 
Thus, Env as an immunogen may 
bypass key steps in the B cell inductive 
pathway, or may actively induce 
negative production or downregulation 
of production of some broadly 
neutralizing antibodies [52–54]. 
The receptor–ligand interactions 
and intracellular signaling pathways 
that govern the production of antibody-
producing plasma cells and the 
persistence of plasma and memory B 
cells are poorly understood. Additional 
information on the mechanisms 
responsible for B cell migration, 
selection, and differentiation within 
and between specialized anatomical 
sites, particularly within lymphoid 
follicles, might be used to target 
suitable Env epitopes to appropriate 
B cell inductive pathways. An example 
would be to provide necessary signals 
to generate long-lived and high afﬁnity 
memory in the marginal zone B cell 
compartment. Another example would 
be to discover ways to modify germinal 
center formation, positive and negative 
selection, and B cell differentiation to 
drive long-lived high afﬁnity antibody 
responses against key epitopes that 
tend to be poorly immunogenic.
In parallel to these efforts, genetic 
studies at the population level could 
provide critical information on the 
most promising paths to follow. In 
particular, the recent completion of 
the International HapMap Project 
now permits whole genome associated 
studies to be conducted with a 
minimum number of single nucleotide 
polymorphism tags [55,56]. This 
powerful new technology could be used 
to identify genes that are associated 
with the wide variation in neutralizing 
antibody responses in HIV-1-infected 
individuals and in vaccine recipients. A 
critical question to ask is whether the 
potent neutralizing antibody response 
in a small subset of infected individuals 
is due to unique viral epitopes or to 
host genetic polymorphisms. Current 
evidence suggests that both might 
make a substantial contribution in 
the context of combined epitope and 
allelic representations [28,47,57].
To date most studies of the humoral 
responses in HIV infections have 
investigated immunoglobulins, the 
ﬁnal product of B cell responses. 
Relatively few studies have examined B 
cell immunopathogenesis. A number 
of basic questions are still unanswered 
(e.g., extent and reason for 
perturbation of B cell subset changes, 
including memory B cells and plasma 
cells, in peripheral blood and tissues). 
Questions also remain about other 
potential functional contributions of 
B cells to HIV infections (e.g., role 
as antigen-presenting cells). In vivo 
studies should be performed in the 
nonhuman primate animal model to 
determine the emergence of pathologic 
events in the B cell compartment, 
in particular in lymphatic and 
gastrointestinal tissues of naïve and 
vaccinated animals that are challenged 
with pathogenic SIV or SHIV. These 
investigations should be done in 
parallel to detailed analyses of the 
magnitude and function of HIV-speciﬁc 
immunoglobulin responses determined 
in plasma and tissue secretions, and 
of HIV-speciﬁc B cells on a single cell 
basis.
The establishment of a research 
consortium to study fundamental B cell 
biology as it relates to HIV-1 vaccines 
is recommended. This program 
should be structured in a way that asks PLoS Medicine  |  www.plosmedicine.org 1870 December 2007  |  Volume 4  |  Issue 12  |  e348
key scientiﬁc questions about B cell 
regulatory pathways that modulate Env 
immunogenicity. Studies could address 
B cell receptor–ligand interactions and 
intracellular signaling pathways that 
govern the production of antibody-
producing plasma cells, the persistence 
of plasma and memory B cells, the 
mechanism of action of adjuvants, and 
host genetic associations with immune 
responses.  
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